PHARMACY

Eli Lilly to present lung cancer studies at upcoming conference

BY Alaric DeArment

INDIANAPOLIS A U.S. drug maker plans to present more than 30 lung cancer studies at the International Association for the Study of Lung Cancer’s 13th World Conference on Lung Cancer in San Francisco.

Eli Lilly & Co. announced Monday that it would present data from studies involving drugs such as Alimta (pemetrexed), as a treatment for nonsquamous non-small cell lung cancer, and Gemzar (gemcitabine hydrochloride) at the conference, which takes place between Friday and Aug. 4.

“Our goal is, and always has been, to improve treatment options for individual patients,” Lilly VP cancer research Richard Gaynor said in a statement. “In lung cancer in particular, histology provides us with one way to tailor treatment with Alimta for patients living with nonsquamous NSCLC.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

NACDS urges House to improve Part D, control prescription drug expenditures in healthcare reform legislation

BY Alaric DeArment

ALEXANDRIA, Va. Retail pharmacy chains hope to see changes to Medicare Part D and assistance in controlling prescription drug expenditures included in the America’s Affordable Health Choices Act of 2009, according to a letter delivered to members of the House this week.

In the letter – written to House Ways and Means Committee chairman Chuck Rangel, D-N.Y., House Energy and Commerce Committee chairman Henry Waxman, D-Calif., and the committees’ ranking Republicans – National Association of Chain Drug Stores president Steven Anderson praised sections of the bill designed to cover the Medicare Part D coverage gap. The gap, also called the doughnut hole, causes seniors to lose Part D coverage when their annual prescription drug expenditures are between $2,700 and $6,154.

Anderson urged policies including a clarification of language ensuring that pharmacies would not be expected to cover the discounted portion of the price of a drug covered under Part D; expansion of extended days’ supplies of drugs – such as 90-day supplies – as a way to reduce dispensing fees and copays; and a rolling Part D enrollment period to alleviate disruptions in care that he said resulted from current enrollment rules.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Teva settles patent suit with Ortho-McNeil-Janssen

BY Allison Cerra

JERUSALEM Teva Pharmaceutical Industries has announced its settlement of its patent infringement lawsuit over its generic version of a popular contraceptive.

Teva said it has entered into a definitive agreement with Ortho-McNeil-Janssen to settle the suit in the U.S. District Court for the District of New Jersey related to Teva’s generic  Ortho Tri-Cyclen Lo. Under the terms of the settlement, Teva will obtain a release for past sales of its generic product, in exchange for an undisclosed royalty payment. Teva also will obtain a license to re-enter the market on December 31, 2015, or earlier in certain circumstances.

The settlement will not become effective until the court enters a proposed consent judgment upholding the validity and enforceability of Ortho’s patent.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?